Join the conversation that will center around actions, outsourcing strategies and tactics that biotechs can take to positively impact their clinical outsourcing plans. The conversation will cover a number of topics as well as give you a chance to probe for more information, including:
What are the benefits of group purchasing power?
What do the CROs get out of this?
How can technology assist and to increase transparency with business partners?
Our Panelists Are Ready to Answer Your Questions!
Leif Kuse, CEO, Pharall
Leif has a vast business experience in the field of clinical outsourcing since 2004. Including vendor management, budgeting & project controlling for biotech companies, CROs and the pharmaceutical industry. He implemented various governance models for big pharma companies and managed various partnerships between CROs and Pharma companies. He was Head of Purchasing at Fresenius Biotech, Germany, and also held investment management positions at different venture capital funds after finishing his academic studies in business administration and law. Pharall is the world’s first group purchasing organization in clinical drug development, leveraging trust, quality and efficiency between Biotechs and CROs.
Anca Copaescu, CEO, Strategikon
Frustrated by current solutions, Anca created the Clinical Maestro platform based on more than 15 years’ experience in clinical research with both sponsors and service providers. As Head of Clinical Outsourcing at BioMarin, and with experience at two global CROs, Anca gained unique insights into clinical business operation. Clinical Maestro addresses the entire clinical study financial process: from planning, to outsourcing, to the end of the clinical contract and study analytics. Strategikon’s Clinical Maestro® platform and its Sponsor modules, PORTFOLIO, SOURCE, LEAD, and VISION – each reducing time and expenses to develop clinical trials from the beginning to end.